Your browser doesn't support javascript.
loading
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp, Andrew R; James, Elizabeth C; McNeish, Iain A; Dean, Andrew; Kim, Jae-Won; O'Donnell, Dearbhaile M; Gallardo-Rincon, Dolores; Blagden, Sarah; Brenton, James; Perren, Tim J; Sundar, Sudha; Lord, Rosemary; Dark, Graham; Hall, Marcia; Banerjee, Susana; Glasspool, Rosalind M; Hanna, C Louise; Williams, Sarah; Scatchard, Kate M; Nam, Helena; Essapen, Sharadah; Parkinson, Christine; McAvan, Lucy; Swart, Ann Marie; Popoola, Babasola; Schiavone, Francesca; Badrock, Jonathan; Fananapazir, Fuad; Cook, Adrian D; Parmar, Mahesh; Kaplan, Richard; Ledermann, Jonathan A.
Affiliation
  • Clamp AR; The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
  • James EC; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Electronic address: E.james@ucl.ac.uk.
  • McNeish IA; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Dean A; Oncology, St John of God Hospital, Subiaco, WA, Australia.
  • Kim JW; Department of Obstetrics and Gynecology, Seoul National University, Seoul, South Korea.
  • O'Donnell DM; Cancer Trials Ireland, Dublin, Ireland.
  • Gallardo-Rincon D; Department of Medical Oncology, Instituto Nacional de Cancerologia, Mexico City, Mexico.
  • Blagden S; Department of Oncology, Churchill Hospital, University of Oxford, Oxford, UK.
  • Brenton J; Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Perren TJ; Leeds Institute of Medical Research, St James' University Hospital, Leeds, UK.
  • Sundar S; Institute of Cancer and Genomics, University of Birmingham, Birmingham, UK.
  • Lord R; Department of Oncology, Clatterbridge Cancer Centre, Wirral, UK.
  • Dark G; Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.
  • Hall M; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
  • Banerjee S; Gynaecological Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
  • Glasspool RM; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Hanna CL; Department of Oncology, Velindre Cancer Centre, Cardiff, UK.
  • Williams S; Birmingham City Hospital, Birmingham, UK.
  • Scatchard KM; North Devon District Hospital, Barnstaple, UK; Exeter Oncology Centre, Royal Devon and Exeter Hospital, Exeter, UK.
  • Nam H; Broomfield Hospital, Chelmsford, UK; Southend University Hospital, Southend, UK.
  • Essapen S; St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK.
  • Parkinson C; Cambridge Cancer Centre, Addenbrooke's Hospital, Cambridge, UK.
  • McAvan L; Department of Oncology, University Hospital Coventry and Warwickshire, Coventry, UK.
  • Swart AM; Norwich Clinical Trials Unit, Norwich Medical School, University of East Anglia, Norwich, UK.
  • Popoola B; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Schiavone F; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Badrock J; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Fananapazir F; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Cook AD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Parmar M; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Kaplan R; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Ledermann JA; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute and UCL Hospitals, London, UK.
Lancet Oncol ; 23(7): 919-930, 2022 07.
Article in En | MEDLINE | ID: mdl-35690073
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Country of publication: